JB Pharma

What JB Pharma does

JB Pharma (J.B. Chemicals & Pharmaceuticals Limited) is an Indian pharmaceutical company founded in 1976 and headquartered in Mumbai, operating across branded generics, API manufacturing, contrast media diagnostics, and CDMO services. The company produces a portfolio of 350+ brands spanning 20 therapeutic areas — gastroenterology (Metrogyl, Rantac), cardiovascular/hypertension (Cilacar, Nicardia), diabetes (Dapacose, Vilcose), nephrology (Midotab), respiratory/cough (Zecuf, Nosmok), wound care (Cadomer), and antivirals — across dosage forms including tablets, capsules, injectables, IV infusions, liquids, topicals, lozenges, and sachets. Manufacturing runs through 8 globally accredited facilities in Gujarat (Panoli campus, Ankleshwar, Daman) producing billions of tablets and hundreds of millions of bottles annually, with multi-form accreditations from USFDA, EU-GMP, UK MHRA, TGA Australia, SAHPRA, ANVISA, and WHO-GMP. Vertically integrated API capabilities cover Diclofenac Sodium, Nifedipine, Atenolol, Cilnidipine, and related molecules, supported by US Drug Master Files and European CEPs across 80+ country registrations.

The business runs on a hybrid revenue model with three primary streams: (i) domestic Indian sales through a field force into 600,000+ pharmacies covering every PIN code; (ii) international formulations across 40+ regulated and semi-regulated markets through wholly owned subsidiaries in South Africa (Biotech Laboratories) and Russia (OOO Unique Pharmaceutical Laboratories) plus distribution partnerships; and (iii) B2B CDMO contracts with global MNCs covering formulation optimization, scale-up, bio-studies, stability testing, regulatory support, and commercial production. Pricing is quote-based and institutional across healthcare providers, pharmacy chains, and MNC partners with no public list pricing. In January 2026, Torrent Pharmaceuticals acquired a controlling stake for approximately ₹12,537 crore, integrating JB Pharma into the Torrent Group as a listed subsidiary (BSE/NSE: JBCHEPHARM). Most recently, JB/Torrent launched generic semaglutide brands capturing 38% domestic market share within the first month, and reported Q3 FY26 revenue of ₹1,065 crore (11% YoY) with 27.8% EBITDA margins.

Name

JB Pharma

Legal name

J. B. Chemicals & Pharmaceuticals Limited

Website

https://jbpharma.com

Company type

Public

Founded year

1976

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

JB Pharma is an Indian pharmaceutical company manufacturing and supplying branded generics, APIs, contrast media, and CDMO services across 20 therapeutic areas for the domestic market and 40+ international markets, operating from 8 globally accredited facilities.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Generic pharmaceuticals manufacturing
• Active pharmaceutical ingredients
• Contract manufacturing services
• Contrast media products
• Branded formulation medicines

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Domestic Formulations: Domestic Indian pharmaceutical formulations business with 350+ brands across 20 key therapeutic areas including gastroenterology, hypertension, diabetes, dermatology, nephrology, respiratory, anti-infectives, and pain management. Brands available across 600,000+ pharmacies covering every PIN code in India. 5 brands feature in India's top 300 pharmaceutical brands.
2. International Formulations: Export of pharmaceutical formulations to 40+ regulated and semi-regulated markets. Wholly owned subsidiaries in South Africa (Biotech Laboratories) and Russia with direct operations. Generics exported to USA, UK, Europe, South Africa, Australia, Canada. Branded generics exported to Africa, South-East Asia, Gulf, Middle East, Central and South America.
3. CDMO Services: Contract Development and Manufacturing Operations services for large MNCs worldwide. Manufacturing tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. Services include formulation optimization, scale-up services, bio-studies, stability testing, validation batches, regulatory support, packaging design, and commercial production. Currently serving markets like USA, UK, Australia, Brazil, Canada, South Africa.
4. API Manufacturing: Active Pharmaceutical Ingredients manufacturing with product registrations in 80+ countries. Major products include Diclofenac Sodium (one of India's largest manufacturers), Diclofenac Diethylamine, Nifedipine, Atenolol, Cilnidipine, Ciprofloxacin HCl, Cetirizine HCl, Meclizine HCl. WHO-GMP certificates for all plants, USFDA, EU GMP, and multiple regulatory approvals.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

JB Pharma manufactures and sells 350+ branded generic pharmaceutical formulations across 20 therapeutic areas, produces Active Pharmaceutical Ingredients (notably Diclofenac Sodium), supplies contrast media products for X-Ray, MRI and Ultrasound diagnostics, and provides Contract Development and Manufacturing Operations (CDMO) services to global pharmaceutical companies. Products are produced at 8 globally accredited manufacturing facilities in Gujarat, India (Panoli, Ankleshwar, Daman) with USFDA, EU-GMP, UK MHRA, TGA Australia, SAHPRA and WHO-GMP certifications, and are sold through a direct field sales force in India, wholly owned subsidiaries in South Africa and Russia, and distribution partners across 40+ countries.

Product overview

JB Pharma is a diversified pharmaceutical company offering a broad portfolio of branded generic medicines, active pharmaceutical ingredients (APIs), and contract manufacturing services. The product portfolio spans 20 therapeutic areas including gastroenterology (Metrogyl, Rantac), cardiovascular/hypertension (Cilacar, Nicardia), diabetes (Dapacose, Vilcose), respiratory/cough (Zecuf, Nosmok), wound care (Cadomer), and nephrology (Midotab). The company operates 8 manufacturing facilities in Gujarat with 40+ global regulatory accreditations including USFDA and EU-GMP, exports to 40+ regulated and semi-regulated markets, and maintains wholly owned subsidiaries in South Africa and Russia. Through its CDMO business, JB Pharma offers contract development and manufacturing for lozenges, tablets, injectables, and other dosage forms to pharmaceutical partners worldwide. The company also ranks among India's top players in contrast media/radio diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• Cilacar: Leading brand in cardiology and nephrology (Calcium Channel Blocker)
• Rantac
• Nicardia
• Metrogyl
• Doktor Mom
• Rinza

Products and services

• Metrogyl Metronidazole-based antibiotic and anti-protozoal medication available in tablets, IV, suspension and gel formulations including Metrogyl ER (extended release) and Metrogyl O (combination with ofloxacin). Used across gastroenterology and anti-infective therapy for Indian patients.
• Rantac Ranitidine-based anti-peptic ulcer medication available in tablets, injections and suspensions, including variants Rantac DOM (with domperidone), Rantac MPS (antacid suspension) and Rantac R/RD (with rabeprazole). For Indian patients with peptic ulcer and related gastric conditions.
• Cilacar Cilnidipine-based calcium channel blocker for hypertension management available as standalone and combination products including Cilacar-T (with telmisartan), Cilacar-M (with metoprolol), Cilacar-C (with chlorthalidone) and Cilacar NB (with nebivolol). Cilacar is positioned as the #1 CCB brand in the Indian market.
• Nicardia Nifedipine-based calcium channel blocker for hypertension and resistant blood pressure management available in capsules, CD retard and XL extended release formulations. Used in Indian cardiology and blood pressure management.
• Cadomer Cadexomer iodine-based wound care ointment for acute and chronic wound healing, available in 10gm and 20gm packaging. Targeted at patients requiring wound management therapy.
• Zecuf Herbal cough remedy available as lozenges and syrups in multiple flavors including sugar-free options, with ingredients such as tulsi and yashtimadhu. For Indian patients seeking respiratory/cough therapy.
• Nosmok Nicotine polacrilex lozenges for nicotine replacement therapy (NRT) available in 2mg and 4mg doses. For patients seeking smoking cessation support.
• Dapacose Dapagliflozin-based SGLT2 inhibitor for diabetes management, available in 5mg and 10mg tablets. For Indian patients with type 2 diabetes.
• Vilcose Vildagliptin-based DPP-4 inhibitor for diabetes management available as standalone and in combination with metformin sustained release (Vilcose-M SR). For Indian patients with type 2 diabetes.
• Midotab Midodrine hydrochloride tablets for nephrology care, available in 2.5mg and 5mg doses for managing orthostatic hypotension and renal conditions. For Indian patients requiring nephrology therapy.
• Active Pharmaceutical Ingredients (APIs) API manufacturing business with 20+ years of experience, including Diclofenac Sodium (one of India's largest manufacturers), Diclofenac Diethylamine, Nifedipine, Atenolol, Cilnidipine, Ciprofloxacin HCl, Cetirizine HCl and Meclizine HCl with product registrations in 80+ countries. EU GMP approved facility for Diclofenac Sodium, Nifedipine and Atenolol. Supplied to leading global research-based and generic pharmaceutical companies.
• Radio Diagnostics / Contrast Media Contrast media products for X-Ray, MRI and Ultrasound diagnostics including Cardiolek (iodixanol), Trazograf, Lek-Pamidol (iopamidol), Contrapaque (iohexol), Magnilek (gadopentetate) and Gadotrast (gadoteric acid). JB Pharma is ranked #2 in India for contrast media by sales value with 30+ years of experience and product registrations in 30+ countries. For large corporate and government hospitals and diagnostic centres.
• CDMO Services (Contract Development and Manufacturing Operations) Contract manufacturing and development services for tablets, capsules, injectables, gels, creams, ointments, liquid herbal syrups and lozenges. Currently serves markets including USA, UK, Australia, Brazil, Canada and South Africa. Services include formulation optimization, scale-up, bio-studies, stability testing, validation batches, regulatory support, packaging design and commercial production. For large multinational pharmaceutical companies requiring outsourced manufacturing capacity.
• Lozenges (CDMO) Contract Development and Manufacturing Operations for lozenges including centre-filled soft-centred, powder-filled, herbal and medicated lozenges in various shapes and flavors with sugar and sugar-free options. JB Pharma is one of the 3 largest lozenge manufacturers globally with 2 decades of experience exporting to 40+ countries. For global pharmaceutical partners seeking outsourced lozenge manufacturing.

Quantifiable outcome

• 6 brands in Top 300 Domestic Formulation Brands in India
• +7 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Biotech Laboratories (Pty) Ltd., South AfricacoreOthersJB Pharma made a strategic investment in Biotech Laboratories in 2007, which became a wholly owned subsidiary. The company markets, sells, and distributes generic and branded pharmaceuticals to both private and public sectors in South Africa, Namibia, Botswana, Zimbabwe, Mozambique, Swaziland, and Lesotho. Biotech Labs launched a large animal health division in 2011 partnering with Norbrook Laboratories.
• Norbrook LaboratoriesminorStrategic or Co-development PartnerNorbrook Laboratories, a leading global veterinary research and development company based in the United Kingdom, partnered with Biotech Laboratories (JB Pharma's South African subsidiary) in 2011 to launch a large animal health division.
• Johnson & JohnsonminorStrategic or Co-development PartnerJB Pharma divested its OTC business to Johnson & Johnson in 2011 while continuing to develop its prescription business in the Russian and CIS markets.
• Large MNCs (CDMO customers)coreOEM/ Whitelabel/ Licensing PartnerJB Pharma has long-lasting global partnerships with large MNCs for contract manufacturing. Services include tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules for markets including USA, UK, Australia, Brazil, Canada, and South Africa. The company provides formulation optimization, scale-up services, bio-studies, stability testing, validation batches, regulatory support, packaging design, and commercial production.

Scale indicators24 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Alkem Laboratories: Mid-sized Indian pharma with highly comparable domestic formulations focus across anti-infectives, gastroenterology and chronic therapies; similar manufacturing footprint and international expansion strategy.
• Sun Pharmaceutical Industries: India's largest pharma company by revenue with chronic therapy leadership, US generics scale and similar specialty product focus. Most direct large-cap comparable for JB's therapeutic mix and CDMO operations.
• Glenmark Pharmaceuticals: Indian pharma of comparable scale focused on branded generics in India, US ANDAs, and API exports. Overlaps with JB in cardiovascular, dermatology and respiratory therapy areas.
• Cipla Limited: India's largest pharma by domestic market share with comparable export distribution, API capabilities, and respiratory/anti-infective franchises. Overlaps directly with JB in cardiology and gastroenterology therapies.
• Torrent Pharmaceuticals Limited: Now the controlling shareholder of JB Pharma following January 2026 acquisition; operates highly comparable India-centric generics business with similar therapeutic categories and global export footprint. Closest direct peer post-acquisition.
• Zydus Lifesciences (formerly Cadila Healthcare): Indian integrated pharma player with comparable domestic brand portfolio, US generics presence, API manufacturing and contract services. Direct competitor in chronic and acute therapy segments JB serves.
• Lupin Limited: Indian generic pharmaceutical manufacturer of comparable scale with strong US generics presence and similar dosage form portfolio (tablets, injectables, APIs). Direct competitor in Indian formulations and export markets.
• Dr. Reddy's Laboratories: Leading Indian generics company with comparable international footprint, API+formulations integration, and US FDA-accredited facilities. Direct competitor in both Indian branded generics and regulated-market generics exports.
• Aurobindo Pharma: India-based generics manufacturer with significant US formulations and API exposure; comparable API-to-formulations vertical model and contract manufacturing operations serving regulated markets.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad overlapping capabilities in CDMO, API and finished generic formulations; sets global pricing benchmarks impacting JB's regulated-market exports.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/onejbglobal
• Facebookfacebook.com/103796288048292
• LinkedInlinkedin.com/company/j-b-chemicals-pharmaceuticals-limited

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JB Pharma